AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICERPRNewsWire • 04/22/26
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 04/08/26
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better BuySeeking Alpha • 04/07/26
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye DiseaseZacks Investment Research • 04/07/26
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.Barrons • 04/06/26
Amgen Unveils Upbeat Results For Tepezza After Rival Eye Disease Drug DisappointsInvestors Business Daily • 04/06/26
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASEPRNewsWire • 04/06/26
Amgen (AMGN) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 04/02/26
Trump threatens 100% tariff on US drug makers that don't strike deals to lower pricesThe Guardian • 04/02/26
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction TerritoryThe Motley Fool • 04/02/26
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager TherapyBusiness Wire • 04/01/26
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSISPRNewsWire • 03/28/26